Switching long acting antipsychotic medications to aripiprazole long acting once-a-month: expert consensus by a panel of Italian and Spanish psychiatrists

References

• Lieberman JA, Stroup TS, McEvoy JP, et al.; Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE) Investigators. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia [published correction appears in N Engl J Med. 2010;363:1092-1093]. N Engl J Med. 2005;353:1209–1223.
   PubMed Web of Science ®Google Scholar
• Fagiolini A, Brugnoli R, Di Sciascio G, et al. Switching antipsychotic medication to aripiprazole: position paper by a panel of Italian psychiatrists. Expert Opin Pharmacother. 2015;16:727–737.
   PubMed Web of Science ®Google Scholar
• Brissos S, Ruiz Veguilla M, Taylor D, et al. The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal. Ther Adv Psychopharmacol. 2014;4(5):198–219.
   PubMedGoogle Scholar
• Croxtall JD. Aripiprazole: a review of its use in the management of schizophrenia in adults. CNS Drugs. 2012;26(2):155–183.
   PubMed Web of Science ®Google Scholar
• Lambert TJ. Switching antipsychotic therapy: what to expect and clinical strategies for improving therapeutic outcomes. J Clin Psychiatry. 2007;68 Suppl 6:10–13.
   PubMed Web of Science ®Google Scholar
• Naber D, Hansen K, Forray C, et al. QUALIFY: a randomized head-to-head study of aripiprazole once-monthly and paliperidone palmitate in the treatment of schizophrenia. Schizophr Res. 2015;168(1–2):498–504.
   PubMed Web of Science ®Google Scholar
• Abilify Maintena. Summary of product characteristics, European Medicine Agency. 2016 [cited 2016 Jan 7]. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002755/WC500156111.pdf
   Google Scholar
• Abilify Maintena. US prescribing information [cited 2015 Dec 27]. Available from: http://www.otsuka-us.com/products/Documents/Abilify.M.PI.pdf
   Google Scholar
• Shirley M, Perry CM. Aripiprazole (Abilify Maintena®): a review of its use as maintenance treatment for adult patients with schizophrenia. Drugs. 2014;74(10):1097–1110.
   PubMed Web of Science ®Google Scholar
• Fleischhacker WW, Sanchez R, Johnson B, et al. Long-term safety and tolerability of aripiprazole once-monthly in maintenance treatment of patients with schizophrenia. Int Clin Psychopharmacol. 2013;28(4):171–176.
   PubMed Web of Science ®Google Scholar
• Kane JM, Peters-Strickland T, Baker RA, et al. Aripiprazole once-monthly in the acute treatment of schizophrenia: findings from a 12-week, randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2014;75(11):1254–1260.
   PubMed Web of Science ®Google Scholar
• Oya K, Kishi T, Iwata N. Efficacy and tolerability of aripiprazole once monthly for schizophrenia: a systematic review and meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2015;11:2299–2307.
   PubMed Web of Science ®Google Scholar
• Mallikaarjun S, Kane JM, Bricmont P. Pharmacokinetics, tolerability and safety of aripiprazole once-monthly in adult schizophrenia: an open-label, parallel-arm, multiple-dose study. Schizophr Res. 2013;150(1):281–288.
   PubMed Web of Science ®Google Scholar
• Kahn RS, Giannopoulou A. The safety, efficacy and tolerability of Abilify Maintena for the treatment of schizophrenia. Expert Rev Neurother. 2015;15(9):969–981.
   PubMed Web of Science ®Google Scholar
• Gopalakrishna G, Aggarwal A, Lauriello J. Long-acting injectable aripiprazole: how might it fit in our tool box? Clin Schizophr Relat Psychoses. 2013;7(2):87–92.
   PubMedGoogle Scholar
• Carpenter WT Jr, Buchanan RW. Expanding therapy with long-acting antipsychotic medication in patients with schizophrenia. JAMA Psychiatry. 2015;72(8):745–746.
   PubMed Web of Science ®Google Scholar
• Nasrallah HA. The case for long-acting antipsychotic agents in the post-CATIE era. Acta Psychiatr Scand. 2007;115(4):260–267.
   PubMed Web of Science ®Google Scholar
• Sim K, Su A, Ungvari GS, et al. Depot antipsychotic use in schizophrenia: an East Asian perspective. Hum Psychopharmacol. 2004;19(2):103–109.
   PubMed Web of Science ®Google Scholar
• Ahn J, McCombs JS, Jung C, et al. Classifying patients by antipsychotic adherence patterns using latent class analysis: characteristics of nonadherent groups in the California Medicaid (Medi-Cal) program. Value Health. 2008;11(1):48–56.
   PubMed Web of Science ®Google Scholar
• Grimaldi-Bensouda L, Rouillon F, Astruc B, et al.; CGS Study Group. Does long-acting injectable risperidone make a difference to the real-life treatment of schizophrenia? Results of the Cohort for the General study of Schizophrenia (CGS). Schizophr Res 2012;134(2–3):187–194.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Wahlbeck K, Lönnqvist J, et al. Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ. 2006;333(7561):224.
   PubMed Web of Science ®Google Scholar
• Tiihonen J, Haukka J, Taylor M, et al. A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry. 2011;168(6):603–609.
   PubMed Web of Science ®Google Scholar
• Alphs L, Benson C, Cheshire-Kinney K, et al. Real-world outcomes of paliperidone palmitate compared to daily oral antipsychotic therapy in schizophrenia: a randomized, open-label, review board-blinded 15-month study. J Clin Psychiatry. 2015;76(5):554–561.
   PubMed Web of Science ®Google Scholar
• Buckley PF, Correll CU. Strategies for dosing and switching antipsychotics for optimal clinical management. J Clin Psychiatry. 2008;69 Suppl 1:4–17.
   PubMed Web of Science ®Google Scholar
• Weiden PJ, Buckley PF. Reducing the burden of side effects during long-term antipsychotic therapy: the role of ‘switching’ medications. J Clin Psychiatry. 2007;68 Suppl 6:14–23.
   PubMed Web of Science ®Google Scholar
• Correll CU. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry. 2010;25 Suppl 2:S12–S21.
   Google Scholar
• Llorca PM, Abbar M, Courtet P, et al. Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness. BMC Psychiatry. 2013;13:340.
   PubMed Web of Science ®Google Scholar
• Voss EA, Ryan PB, Stang PE, et al. Switching from risperidone long-acting injectable to paliperidone long-acting injectable or oral antipsychotics: analysis of a Medicaid claims database. Int Clin Psychopharmacol. 2015;30(3):151–157.
   PubMed Web of Science ®Google Scholar
• Covell NH, McEvoy JP, Schooler NR, et al. Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial. J Clin Psychiatry. 2012;73(5):669–675.
   PubMed Web of Science ®Google Scholar
• Rosa F, Schreiner A, Thomas P, et al. Switching patients with stable schizophrenia or schizoaffective disorder from olanzapine to risperidone long-acting injectable. Clin Drug Investig. 2012;32(4):267–279.
   PubMed Web of Science ®Google Scholar
• Hawley C, Turner M, Latif MA, et al. Switching stable patients with schizophrenia from depot and oral antipsychotics to long-acting injectable risperidone: reasons for switching and safety. Hum Psychopharmacol. 2010;25(1):37–46.
   PubMed Web of Science ®Google Scholar
• Kasper S, Lerman MN, McQuade RD, et al. Efficacy and safety of aripiprazole vs haloperidol for long-term maintenance treatment following acute relapse of schizophrenia. Int J Neuro-psychopharmacol. 2003;6(4):325–337.
   PubMed Web of Science ®Google Scholar